JPMORGAN CHASE & CO - CTI BIOPHARMA CORP ownership

CTI BIOPHARMA CORP's ticker is CTIC and the CUSIP is 12648L601. A total of 121 filers reported holding CTI BIOPHARMA CORP in Q2 2022. The put-call ratio across all filers is 0.46 and the average weighting 0.3%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of CTI BIOPHARMA CORP
ValueSharesWeighting
Q1 2023$4,724,000
+66173.8%
1,124,714
-5.2%
0.00%0.0%
Q4 2022$7,128
-99.9%
1,186,030
+4.1%
0.00%0.0%
Q3 2022$6,630,000
-5.2%
1,139,110
-2.8%
0.00%0.0%
Q2 2022$6,996,000
+38766.7%
1,171,774
+30162.8%
0.00%
Q1 2022$18,000
-14.3%
3,872
-53.4%
0.00%
Q4 2021$21,0000.0%8,303
+14.0%
0.00%
Q3 2021$21,000
-12.5%
7,283
-23.7%
0.00%
Q2 2021$24,000
+9.1%
9,539
+25.5%
0.00%
Q1 2021$22,000
-18.5%
7,601
-10.6%
0.00%
Q4 2020$27,000
+200.0%
8,500
-0.4%
0.00%
Q3 2020$9,000
-10.0%
8,538
-0.0%
0.00%
Q2 2020$10,000
+25.0%
8,539
+0.5%
0.00%
Q1 2020$8,000
-96.9%
8,500
-94.7%
0.00%
Q4 2019$255,000
+4.9%
161,661
-44.5%
0.00%
Q3 2019$243,000
-23.6%
291,481
-22.0%
0.00%
Q2 2019$318,000
-18.9%
373,867
-7.6%
0.00%
Q1 2019$392,000
+26.5%
404,477
-4.0%
0.00%
Q4 2018$310,000
-74.8%
421,492
-25.9%
0.00%
Q3 2018$1,229,000
-27.1%
568,732
+68.1%
0.00%
Q2 2018$1,685,000
+61.4%
338,346
+26.4%
0.00%
Q1 2018$1,044,000
+260.0%
267,752
+147.2%
0.00%
Q4 2017$290,000
+6.6%
108,313
+26.8%
0.00%
Q3 2017$272,000
+750.0%
85,448
+1015.2%
0.00%
Q1 2017$32,0007,6620.00%
Other shareholders
CTI BIOPHARMA CORP shareholders Q2 2022
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 6,535,674$27,449,8319.21%
Bleichroeder LP 3,893,730$16,353,6663.49%
AIGH Capital Management LLC 2,100,000$8,820,0003.25%
Ally Bridge Group (NY) LLC 550,000$2,310,0003.03%
Ghost Tree Capital, LLC 2,000,000$8,400,0002.48%
Bain Capital Life Sciences Investors, LLC 4,702,996$19,7532.47%
Altium Capital Management LP 850,000$3,570,0001.98%
Parkman Healthcare Partners LLC 1,753,630$7,365,2461.60%
BVF INC/IL 8,813,021$37,014,6881.35%
Sio Capital Management, LLC 526,239$2,210,2041.09%
View complete list of CTI BIOPHARMA CORP shareholders